Monday, Aravive Inc (NASDAQ: ARAV) filed its quarterly 10Q for the quarter ended 30 June with the SEC.
To preserve cash, the company terminated Phase 1b/P2 trials of batiraxcept in Clear Cell Renal Cell Carcinoma (ccRCC) and pancreatic adenocarcinoma. It will not continue either the ccRCC or the pancreatic adenocarcinoma programs unless it raises additional capital.
Earlier this month, Aravive’s Phase 3 AXLerate-OC trial evaluating batiraxcept in platinum-resistant ovarian cancer did not meet its primary endpoint of progression-free survival (PFS) in the pre-specified subset of patients naïve to prior bevacizumab treatment.
Advancing ccRCC or pancreatic cancer program would require the company to raise significant additional capital or engage a strategic partner, which would be very difficult in light of recent PROC …
